75 CHF CHF 75.00
AG-MR-C0015-M0011 mgCHF 75.00
AG-MR-C0015-M0055 mgCHF 300.00
AG-MR-C0015-M02525 mgCHF 840.00
|Synonyms||(2R)-2-[[9-Isopropyl-6-(N-methylanilino)purin-2-yl]amino]butan-1-ol; Amyloidβ Forty-Two Inducer 5|
|Purity Chemicals||≥98% (NMR)|
|Appearance||White to off-white solid.|
|Solubility||Soluble in DMSO or ethanol.|
|Reconstitution||Stock solutions can be made up to 10mM in DMSO.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Keep cool and dry.
Protect from light and moisture.
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Roscovitine-related purine with no activity on CDKs (used as control for roscovitine).
- Selectively and potently increases production of extracellular Aβ42 and decreases production of extracellular Aβ38 in cultured cells. Extracellular Aβ40 levels remain stable. Intracellular levels of these amyloids appear to remain stable.
- Alzheimer's Disease (AD) accelerator that interacts with VDAC1, prohibitin and mitofilin, possibly interfering with subcellular compartmentalization and lipid rafts properties, shifting γ-secretase activity toward Aβ42 generation.
- Induces a reversible mitochondrial phenotype reminiscent of the one observed in AD brains.
- Tool to detect inhibitors of Aftin-induced actions (potential anti-AD compounds).
- Small-molecule inducers of Aβ-42 peptide production share a common mechanism of action: K. Bettayeb, et al.; FASEB J. 26, 5115 (2012)
- Aftins increase amyloid-β42, lower amyloid-β38, and do not alter amyloid-β40 extracellular production in vitro: toward a chemical model of Alzheimer's disease?: A. Hochard, et al.; J. Alzheimers Dis. 35, 107 (2013)